Treatment library
Preparing current medications, procedures, devices, and historical context.
This is a neutral treatment library, not a recommendation engine. It covers current medications, surgeries, devices, and major discontinued treatments readers still search so the category is easier to compare in one place.
Cost, dosing, coverage, and availability are editorial summaries for orientation. Verify anything material with a clinician, surgeon, or pharmacist before acting on it.
GLP-1 receptor agonist
Novo Nordisk’s branded semaglutide product for chronic weight management and cardiovascular risk reduction in select adults. It is one of the best-known obesity medications in the U.S. and the benchmark many newer comparisons still reference.
2021
Coverage is highly variable. Some employer and commercial plans cover it for obesity, many do not, and prior authorization is common.
Dual GIP and GLP-1 receptor agonist
Eli Lilly’s branded tirzepatide product for chronic weight management. It is the leading dual GIP/GLP-1 branded obesity therapy in current U.S. practice.
2023
Coverage varies sharply by plan and employer policy. Prior authorization and obesity-benefit exclusions remain common.
GLP-1 receptor agonist (oral small molecule)
Eli Lilly's oral orforglipron product for chronic weight management, and the first small-molecule GLP-1 pill approved for weight loss in the United States. It can be taken at any time of day without food or water restrictions, which sets it apart from injectable GLP-1 options and from Novo Nordisk's oral semaglutide.
2026
Coverage is expected to vary sharply by plan and employer policy, consistent with the broader pattern for branded obesity medications. Prior authorization is likely to be common.
GLP-1 receptor agonist
Novo Nordisk’s branded liraglutide product for chronic weight management. It predates the weekly semaglutide and tirzepatide era and remains part of the obesity-medication landscape.
2014
Coverage is inconsistent and has often become less favorable as plans reassess obesity benefits and newer brands enter the market.
Sympathomimetic appetite suppression plus antiepileptic-related appetite effects
A fixed-dose combination of phentermine and topiramate extended release for chronic weight management. It remains one of the main non-GLP-1 branded obesity medications in the U.S.
2012
Coverage varies. Some plans treat it more favorably than injectable obesity brands; many still exclude obesity medications broadly.
Central appetite and reward-pathway modulation
A branded naltrexone / bupropion combination approved for chronic weight management. It remains part of the non-GLP-1 obesity toolkit, especially for patients considering oral options.
2014
Insurance treatment varies widely and obesity-drug exclusions still limit access in many plans.
Gastrointestinal lipase inhibition
The branded prescription version of orlistat. It works differently from appetite-suppressing therapies by reducing fat absorption rather than acting through GLP-1 or stimulant pathways.
1999
Coverage varies but cost barriers are usually lower than for branded GLP-1 therapies.
Gastrointestinal lipase inhibition
The lower-dose over-the-counter orlistat product. Alli is relevant because it remains one of the few obesity-adjacent options patients can buy without a prescription.
2007
Not typically covered because it is sold over the counter.
MC4R agonist
A rare-disease obesity therapy for specific genetic obesity syndromes. It is not a mainstream consumer weight-loss medication, but it belongs in a complete treatment library because it represents a very different obesity-treatment use case.
2020
Coverage can be available for labeled rare-genetic indications but requires highly specific diagnosis and authorization pathways.
GLP-1 receptor agonist
Novo Nordisk’s semaglutide brand for type 2 diabetes. It appears in nearly every weight-loss conversation because patients frequently confuse it with Wegovy or compare access paths between the two.
2017
Often easier to cover through diabetes benefits than obesity-only coverage, but plans and diagnosis requirements vary.
Dual GIP and GLP-1 receptor agonist
Eli Lilly’s tirzepatide brand for type 2 diabetes. It is frequently compared with Zepbound because both use tirzepatide but have different labels and access pathways.
2022
Often tied to diabetes diagnosis, formulary rules, and prior authorization rather than obesity-benefit design.
GLP-1 receptor agonist
The oral semaglutide tablet brand for type 2 diabetes. It matters because many readers want a pill option and then discover that oral semaglutide has a different labeled use and dosing context from Wegovy.
2019
Usually tied to diabetes formularies and diagnosis-specific criteria rather than routine obesity coverage.
GLP-1 receptor agonist
Novo Nordisk’s liraglutide diabetes brand. It matters mainly because readers often compare it with Saxenda and want to understand the same-molecule, different-label relationship.
2010
Generally tied to diabetes coverage rules rather than obesity-benefit design.
Sympathomimetic appetite suppression
A long-standing sympathomimetic appetite suppressant approved for short-term obesity treatment. It is still widely recognized and often prescribed, especially because it is far cheaper than newer brands.
1959
Coverage varies, but cash-pay generic cost is often lower than many branded obesity medications.
Sympathomimetic appetite suppression
A short-term sympathomimetic appetite suppressant that predates the modern GLP-1 era by decades. It remains relevant mainly as a lower-cost, older-style obesity medication.
1959
Coverage varies, but generic cash-pay pricing is generally more accessible than newer brands.
Sympathomimetic appetite suppression
Another older sympathomimetic used for short-term obesity treatment. It is still part of the prescription landscape, though far less central to current public conversations than GLP-1 brands.
1959
Varies, but generic cash-pay cost is often relatively modest.
Sympathomimetic appetite suppression
An older short-term sympathomimetic obesity medication that remains available but sits well outside the current branded-incretin spotlight.
1960
Coverage is inconsistent, but cash-pay cost is often lower than branded obesity drugs.